ZA9810081B - Extended release formulation. - Google Patents

Extended release formulation.

Info

Publication number
ZA9810081B
ZA9810081B ZA9810081A ZA9810081A ZA9810081B ZA 9810081 B ZA9810081 B ZA 9810081B ZA 9810081 A ZA9810081 A ZA 9810081A ZA 9810081 A ZA9810081 A ZA 9810081A ZA 9810081 B ZA9810081 B ZA 9810081B
Authority
ZA
South Africa
Prior art keywords
release formulation
extended release
formulation
extended
release
Prior art date
Application number
ZA9810081A
Other languages
English (en)
Inventor
Deborah Marie Sherman
John Ulrick Lamer
John Clifton Clark
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25508423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA9810081(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Prod filed Critical American Home Prod
Publication of ZA9810081B publication Critical patent/ZA9810081B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA9810081A 1997-11-05 1998-11-04 Extended release formulation. ZA9810081B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96432897A 1997-11-05 1997-11-05

Publications (1)

Publication Number Publication Date
ZA9810081B true ZA9810081B (en) 2000-05-04

Family

ID=25508423

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9810081A ZA9810081B (en) 1997-11-05 1998-11-04 Extended release formulation.

Country Status (38)

Country Link
EP (1) EP1028718B1 (fr)
JP (1) JP2001521892A (fr)
KR (1) KR20010031797A (fr)
CN (1) CN1278165A (fr)
AR (1) AR014012A1 (fr)
AT (1) ATE237320T1 (fr)
AU (1) AU747978B2 (fr)
BG (1) BG104397A (fr)
BR (1) BR9813179A (fr)
CA (1) CA2305242A1 (fr)
CL (1) CL2004001705A1 (fr)
CO (1) CO5011060A1 (fr)
CZ (1) CZ20001659A3 (fr)
DE (1) DE69813602T2 (fr)
DK (1) DK1028718T3 (fr)
EA (1) EA200000487A1 (fr)
EE (1) EE04577B1 (fr)
ES (1) ES2196620T3 (fr)
GE (1) GEP20043198B (fr)
HR (1) HRP20000213B1 (fr)
HU (1) HU225238B1 (fr)
ID (1) ID26317A (fr)
IL (1) IL135457A0 (fr)
MA (1) MA24691A1 (fr)
NO (1) NO20002126L (fr)
NZ (1) NZ504460A (fr)
PA (1) PA8462501A1 (fr)
PE (1) PE128699A1 (fr)
PL (1) PL341141A1 (fr)
PT (1) PT1028718E (fr)
SK (1) SK6472000A3 (fr)
SV (1) SV1998000131A (fr)
TR (1) TR200001232T2 (fr)
TW (1) TW555568B (fr)
UA (1) UA77145C2 (fr)
UY (2) UY25234A1 (fr)
WO (1) WO1999022724A2 (fr)
ZA (1) ZA9810081B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0200898A3 (en) * 1999-04-06 2005-09-28 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
EP1178780B1 (fr) * 1999-05-20 2007-07-18 ELAN CORPORATION, Plc Preparations d'inhibiteurs specifiques du recaptage de la serotonine a liberation multiparticulaire regulee
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
AU2002348266A1 (en) * 2001-12-05 2003-06-23 Wyeth Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
AU2002247945A1 (en) * 2001-12-13 2003-06-23 Cadila Healthcare Limited Manufacture of venlafaxine hydrochloride and crystalline polymorphs thereof
AU2002217373A1 (en) * 2002-01-03 2003-07-15 Lek Pharmaceutical And Chemical Company D.D. Controlled release pharmaceutical formulation containing venlafaxine
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations
US20030191347A1 (en) * 2002-03-28 2003-10-09 Rolf Keltjens Venlafaxine base
WO2003082805A1 (fr) 2002-03-28 2003-10-09 Synthon B.V. Sels de venlafaxine faiblement solubles dans l'eau
US6717015B2 (en) 2002-03-28 2004-04-06 Synthon Bv Venlafaxine besylate
FR2845289B1 (fr) 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
CA2415154C (fr) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Preparations a liberation modifiee contenant des inhibiteurs selectifs de la recapture de la serotonine
DE10350194B4 (de) * 2003-10-28 2005-11-10 Bioplanta Arzneimittel Gmbh Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
ATE336988T1 (de) * 2003-07-30 2006-09-15 Pharmathen Sa Venlafaxine hydrochloridformulierungen mit verzögerter freisetzung
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
ATE361743T1 (de) 2004-02-04 2007-06-15 Alembic Ltd Beschichtete minitabletten von venlafaxinhydrochlorid mit verlängerter freisetzung
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
EP2010162A4 (fr) * 2006-04-03 2013-01-09 Isa Odidi Composition d'administration de médicament
WO2007129329A2 (fr) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Préparation pharmaceutique à libération prolongée comprenant du chlorhydrate de venlafaxine
CN102772390B (zh) * 2012-08-16 2014-01-08 乐普药业股份有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
FR3080278B1 (fr) * 2018-04-11 2021-04-30 Ghs Patents Ltd Procede de fabrication d'un spheroide de cannabidiol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
PA8462501A1 (es) 2000-05-24
HK1029056A1 (en) 2001-03-23
UY25234A1 (es) 2000-12-29
HU225238B1 (en) 2006-08-28
PT1028718E (pt) 2003-07-31
MA24691A1 (fr) 1999-07-01
HUP0004287A2 (hu) 2002-04-29
EP1028718B1 (fr) 2003-04-16
JP2001521892A (ja) 2001-11-13
AU1300399A (en) 1999-05-24
WO1999022724A2 (fr) 1999-05-14
PE128699A1 (es) 2000-01-06
EE200000212A (et) 2001-04-16
DE69813602T2 (de) 2003-11-06
BG104397A (en) 2001-02-28
SK6472000A3 (en) 2000-11-07
CL2004001705A1 (es) 2005-06-03
HRP20000213A2 (en) 2000-12-31
IL135457A0 (en) 2001-05-20
TW555568B (en) 2003-10-01
CO5011060A1 (es) 2001-02-28
UA77145C2 (en) 2006-11-15
NO20002126L (no) 2000-05-04
CZ20001659A3 (cs) 2001-10-17
EA200000487A1 (ru) 2000-10-30
CA2305242A1 (fr) 1999-05-14
AR014012A1 (es) 2001-01-31
HUP0004287A3 (en) 2002-05-28
EP1028718A2 (fr) 2000-08-23
ES2196620T3 (es) 2003-12-16
EE04577B1 (et) 2006-02-15
NZ504460A (en) 2003-01-31
ATE237320T1 (de) 2003-05-15
WO1999022724A3 (fr) 1999-07-22
HRP20000213B1 (en) 2004-04-30
ID26317A (id) 2000-12-14
CN1278165A (zh) 2000-12-27
KR20010031797A (ko) 2001-04-16
PL341141A1 (en) 2001-03-26
TR200001232T2 (tr) 2000-12-21
NO20002126D0 (no) 2000-04-26
GEP20043198B (en) 2004-03-25
DE69813602D1 (de) 2003-05-22
AU747978B2 (en) 2002-05-30
SV1998000131A (es) 1999-11-18
DK1028718T3 (da) 2003-07-28
BR9813179A (pt) 2000-08-22
UY25692A1 (es) 2000-03-31

Similar Documents

Publication Publication Date Title
MXPA01005543A (es) Formulacion de liberacion controlada que consta de gnrh-ii.
EG24198A (en) Extended release formulation
IL135295A0 (en) 2-methyl-thieno-benzodiazepine formulation
GB9715751D0 (en) Formulations
ZA984849B (en) Compositions.
ZA9811461B (en) New formulation
HRP20000213B1 (en) Extended release formulation
ZA985669B (en) New formulation
ZA981926B (en) Detergent--package combination.
ZA987058B (en) Substituted 4-benzoylpyrazoles.
ZA987055B (en) Substituted 4-benzoylpyrazoles.
ZA982436B (en) Thiazolimine derivatives.
GB2322867B (en) Release agent
GB9725061D0 (en) Revitalisation formulation
ZA983705B (en) Pregnan-3-ol-20-ones.
ZA987B (en) Substituted 4-benzoylpyrazoles.
GB9706957D0 (en) Formulation
ZA981739B (en) Composition.
ZA981309B (en) 4-aminoalkoxy-1H-benzoimidazoles.
ZA983795B (en) Substituted 4-benzoyl-pyrazoles.
GB9711946D0 (en) Release devices
ZA981307B (en) 4-aminoethoxyindazole derivatives.
ZA9811834B (en) Substititued ß-alanines.
ZA98263B (en) O-fucosyltransferase.
ZA983698B (en) Estrenes.